Anti-Neuroblastoma [FMG25]
Invented by Dr JOHN KEMSHEAD from SHIRE PHARMACEUTICALS
Invented at Imperial Cancer Research Fund
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 151730 |
Applications | FACS |
Antigen/Gene or Protein Targets | Human Neuroblastoma |
Reactivity | Human |
Relevance | Useful diagnostic reagent to differentiate between neuroblastoma and rhabdomyosarcoma. May be useful as one of a panel of reagents to detect and remove tumour cells from bone marrow harvested for autologous transplantation. Also cross reacts with normal brain and peripheral nerve. The antibody does not bind to other small round-cell tumours of childhood. |
Host | Mouse |
Immunogen | Human cutaneous T cell lymphoma (HUT 78), SPF female Balb/c mice were injected i.p with 2 x 10*5 cells in complete Freund's adjuvant. 30 days later a 2nd i.p injection of 2 x 10*5 cells without adjuvant was given. Fusion was 5 days |
Subclass | IgG1 |
Myeloma Used | P3X63Ag8 |
Strain | Balb/c |
Research Area | Cancer, Cell Type or Organelle Marker |
References: 2 entries
Gibson et al. 1987. Int J Cancer. 39(5):554-9. PMID: 3494688.
A monoclonal antibody (FMG25) that can differentiate neuroblastoma from other small round-cell tumours of childhood.
Europe PMC ID: 3494688
Add a reference
References: 2 entries
Gibson et al. 1987. Int J Cancer. 39(5):554-9. PMID: 3494688.
A monoclonal antibody (FMG25) that can differentiate neuroblastoma from other small round-cell tumours of childhood.
Add a reference